GCK-MODY diabetes associated with protein misfolding, cellular self-association and degradation

Department of Clinical Medicine, University of Bergen, N-5020 Bergen, Norway.
Biochimica et Biophysica Acta (Impact Factor: 4.66). 07/2012; 1822(11):1705-15. DOI: 10.1016/j.bbadis.2012.07.005
Source: PubMed


GCK-MODY, dominantly inherited mild fasting hyperglycemia, has been associated with >600 different mutations in the glucokinase (GK)-encoding gene (GCK). When expressed as recombinant pancreatic proteins, some mutations result in enzymes with normal/near-normal catalytic properties. The molecular mechanism(s) of GCK-MODY due to these mutations has remained elusive. Here, we aimed to explore the molecular mechanisms for two such catalytically 'normal' GCK mutations (S263P and G264S) in the F260-L270 loop of GK. When stably overexpressed in HEK293 cells and MIN6 β-cells, the S263P- and G264S-encoded mutations generated misfolded proteins with an increased rate of degradation (S263P>G264S) by the protein quality control machinery, and a propensity to self-associate (G264S>S263P) and form dimers (SDS resistant) and aggregates (partly Triton X-100 insoluble), as determined by pulse-chase experiments and subcellular fractionation. Thus, the GCK-MODY mutations S263P and G264S lead to protein misfolding causing destabilization, cellular dimerization/aggregation and enhanced rate of degradation. In silico predicted conformational changes of the F260-L270 loop structure are considered to mediate the dimerization of both mutant proteins by a domain swapping mechanism. Thus, similar properties may represent the molecular mechanisms for additional unexplained GCK-MODY mutations, and may also contribute to the disease mechanism in other previously characterized GCK-MODY inactivating mutations.

Download full-text


Available from: Torgeir Flatmark, Jul 20, 2014
  • Source
    • "The structural effects of the mutation are related to those previously observed for two mutations in the loop structure itself (S263P and G264S) which, contrary to the R275C mutant, demonstrated a reduced catalytic efficiency. The molecular mechanism proposed for the formation of a high proportion of dimers, when S263P and G264S are expressed in cells (Negahdar et al., 2012), also apply for the R275C mutant protein. "
    [Show abstract] [Hide abstract]
    ABSTRACT: GCK-MODY, dominantly inherited mild hyperglycemia, is associated with more than 600 mutations in the glucokinase gene. Different molecular mechanisms have been shown to explain GCK-MODY. Here, we report a Pakistani family harboring the glucokinase mutation c.823C>T (p.R275C). The recombinant and in cellulo expressed mutant pancreatic enzyme revealed slightly increased enzyme activity (kcat) and normal affinity for α-D-glucose, and resistance to limited proteolysis by trypsin comparable with wild-type. When stably expressed in HEK293 cells and MIN6 β-cells (at different levels), the mutant protein appeared misfolded and unstable with a propensity to form dimers and aggregates. Its degradation rate was increased, involving the lysosomal and proteasomal quality control systems. On mutation, a hydrogen bond between the R275 side-chain and the carbonyl oxygen of D267 is broken, destabilizing the F260-L271 loop structure and the protein. This promotes the formation of dimers/aggregates and suggests that an increased cellular degradation is the molecular mechanism by which R275C causes GCK-MODY.
    Full-text · Article · Aug 2013 · Molecular and Cellular Endocrinology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Glucokinase is the predominant hexokinase expressed in hepatocytes and pancreatic β-cells, with a pivotal role in regulating glucose-stimulated insulin secretion, illustrated by glucokinase gene mutations causing monogenic diabetes and congenital hyperinsulinemic hypoglycemia. A complex tissue-specific network of mechanisms regulates this enzyme, and a major unanswered question in glucokinase biology is how post-translational modifications control the function of the enzyme. Here, we show that the pancreatic isoform of human glucokinase is SUMOylated in vitro, using recombinant enzymes, and in insulin-secreting model cells. Three N-terminal lysines unique for the pancreatic isoform (Lys-12/Lys-13 and/or Lys-15) may represent one SUMOylation site, with an additional site (Lys-346) common for the pancreatic and the liver isoform. SUMO-1 and E2 overexpression stabilized preferentially the wild-type human pancreatic enzyme in MIN6 β-cells, and SUMOylation increased the catalytic activity of recombinant human glucokinase in vitro and also of glucokinase in target cells. Small ubiquitin-like modifier conjugation represents a novel form of post-translational modification of the enzyme, and it may have an important regulatory function in pancreatic β-cells.
    Full-text · Article · Jan 2013 · Journal of Biological Chemistry
  • [Show abstract] [Hide abstract]
    ABSTRACT: The ubiquitin proteasome system is important to maintain pancreatic beta cell function. Inhibition of the proteasome significantly reduced glucose-induced insulin secretion. Key regulators of the stimulus-secretion cascade seem to be affected by protein misfolding, if the proteasome is down-regulated as recently reported in humans with type 2 diabetes. It remains unknown, however, whether the glucose sensor enzyme glucokinase is involved in this process. A direct interaction between glucokinase and ubiquitin could be shown in vivo by fluorescence resonance energy transfer suggesting regulation of glucokinase by the proteasome. After proteasome inhibition glucokinase activity was significantly reduced in MIN6 cells, whereas the protein content was increased indicating protein misfolding. Enhancing the availability of chaperones by cycloheximide could induce refolding and restored glucokinase activity. Glucokinase aggregation due to proteasome blocking with MG132, bortezomib, epoxomicin or lactacystin could be detected in MIN6 cells, single primary beta cells and hepatocytes using fluorescence-based assays. Glucokinase aggresome formation proceeded microtubule assisted and was avoided by cycloheximide. Thus, our results provide support for glucokinase misfolding and aggregation in case of a diminished capacity of the ubiquitin proteasome system in pancreatic beta cells. In the type 2 diabetic situation this could contribute to reduced glucose-induced insulin secretion.
    No preview · Article · Sep 2013 · Biochemical Journal
Show more